Theriva Biologics Announces Sale of Antibiotic-Degrading Enzyme Portfolio to Biossil Labs Inc.

Article summary

Theriva Biologics has divested its portfolio of antibiotic-degrading enzymes, including SYN-004, SYN-007, and SYN-006, to Biossil Labs Inc. for an upfront payment and potential future milestone and royalty payments.